DM Clinical Research Forms Inaugural Advisory Board to Accelerate Growth and Innovation

HOUSTON, Oct. 8, 2025 /PRNewswire/ — DM Clinical Research, a leading multi-therapeutic site network, today announced the formation of its inaugural Advisory Board. Comprising respected leaders from clinical research and healthcare, the Board will provide strategic counsel to DM Clinical’s Executive Leadership Team on growth priorities, operational excellence, and emerging trends shaping the future of clinical trials.

“As we enter an exciting phase of growth, we are honored to partner with such distinguished leaders,” said Mohammad Millwala, CEO. “As a privately held, founder-led organization, our leadership team is accountable for executing a data-driven expansion plan. The Advisory Board’s expertise and networks will help us scale responsibly while advancing patient-centric research.”

The Advisory Board includes leaders such as Kushal Gohil, SVP, Global Project Leadership & Launch Excellence at Parexel. Gohil brings decades of leadership experience across the CRO sector, with a track record in large-scale organizational initiatives spanning operations, corporate strategy, corporate development, sales operations, brand management, market research, and account management. He holds an MBA from MIT Sloan, a Bachelor of Pharmacy from the University of Pune, and master’s degrees in Drug Development and Marketing from the University of Cincinnati.

“I’m honored to join DM Clinical Research’s inaugural Advisory Board,” said Gohil. “Patients and sites are at the heart of every clinical trial, and I’m excited to help advance DM Clinical’s mission to deliver innovative solutions that put patients first, empower sites, and drive meaningful progress in clinical research.”

About DM Clinical Research

DM Clinical Research is an integrated multi-therapeutic national network of clinical trial sites headquartered in Houston, Texas. Founded in 2006, the company includes over 35 research centers and physician practice embedded sites, servicing a range of therapeutic areas across the nation. DM Clinical Research received the 2024 Society for Clinical Research Sites Site Spark Award and the 2023 Best Clinical Trial Network Award by World Vaccine Congress. Through its partnerships with prominent global pharmaceutical sponsors, DM Clinical Research brings opportunities to the community to participate in cutting-edge research under the careful medical supervision of qualified physicians and professionals. For more information, please visit dmclinical.com or call (281) 517-0550.

View original content:https://www.prnewswire.com/news-releases/dm-clinical-research-forms-inaugural-advisory-board-to-accelerate-growth-and-innovation-302576284.html

SOURCE DM Clinical Research

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

4 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

4 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

4 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

4 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

4 hours ago